| nAChR agonist administered via a preservative-free, low-volume (0.05 mL), aqueous nasal spray |
| Increases endogenous tear film production by stimulating the NLR/TPP |
| Improves signs and symptoms of DED in 4- and 12-week studies |
| Most common adverse events are non-ocular (sneezing and cough) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.